Alice Bernard-Tessier

9PUBLICATIONS
139CO-AUTHORS
ChemotherapyMolecular targetsNeurology and neuromuscular diseasesPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 02, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

|Oct 02, 2025
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond.

Alice Bernard-Tessier, Natacha Naoun, Solenn Barraud

|Aug 07, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Mihaela Aldea, Emeline Orillard, Alice Bernard-Tessier

|Jul 21, 2025
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier

|Mar 05, 2025
A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma.

Sumanta K Pal, Alice Bernard-Tessier, Peter Grell

|Feb 01, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.

Tanya Dorff, Lisa G Horvath, Karen Autio

Pageof 2

Frequent Collaborators

2 joint publications

Sylvie Rottey

2 joint publications

Xin Gao

2 joint publications

Richard Greil

2 joint publications

Mehmet A Bilen